Evidence map›Paper›PMID 40259456›Full record

ArticleEuropean journal of immunology2025

Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Courses.

C Dörnte, A Datsi, V Traska, J Kostyra, M Wagner, O Brauns, C Lamsfuß, H Winkels, V Balz, J Enczmann and 11 more

Abstract read
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

C DörnteMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.ORCID 0000-0002-7417-4658
A DatsiInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University Düsseldorf, Düsseldorf, Germany.
V TraskaMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
J KostyraMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
M WagnerMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
O BraunsMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
C LamsfußMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
H WinkelsClinic III for Internal Medicine, University of Cologne Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
V BalzInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University Düsseldorf, Düsseldorf, Germany.
J EnczmannInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University Düsseldorf, Düsseldorf, Germany.
O AdamsInstitute for Virology, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University, Düsseldorf, Germany.
L MuellerInstitute for Virology, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University, Düsseldorf, Germany.
H BaurmannMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
B Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Medizinische Hochschule Hannover, Hannover, Germany.
A BonifaciusInstitute of Transfusion Medicine and Transplant Engineering, Medizinische Hochschule Hannover, Hannover, Germany.
R V SorgInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University Düsseldorf, Düsseldorf, Germany.
C DoseMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
J SchmitzMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
A RichterMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.
J FischerInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty and University Hospital Düsseldorf Heinrich Heine-University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-2079-1845
M SchusterMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany.

Funding

North Rhine-Westphalia MIL-1-1
6 · The paper itself

Abstract

Infection with SARS-CoV-2 results in mild to severe COVID-19 disease courses. Several studies showed the association of impaired T-cell responses and certain HLA haplotypes with disease severity. However, it remained unclear if T-cell activation was compromised due to a general reduction of presented epitopes or other intrinsic factors within APCs or T cells. Furthermore, a potential reduction of presented epitopes would suggest if an upcoming SARS-CoV-2 variant could escape T-cell immunity. Hence, knowledge about the T-cell epitope landscape of SARS-CoV-2 would allow to better understand mechanisms leading to severe disease and to estimate the potential stability of the T-cell response in light of virus evolution, which might provide insights for future vaccine designs. Hence, in the present study, the T-cell epitope landscape of SARS-CoV-2 was determined via in vitro T-cell stimulation plus in silico prediction. HLAs associated with mild and severe disease courses showed almost the same potential in epitope presentation, suggesting intrinsic factors of APCs or T cells as contributors to the more severe disease courses. As T-cell epitopes did also not originate from regions of SARS-CoV-2 having shown high mutation rates in the past, a relatively stable T-cell response can be expected regarding new SARS-CoV-2 strains in the future. Analysis of the T-cell epitope landscape of SARS-CoV-2 suggests T-cell intrinsic factors as likely modulators of disease severity and that the capacity of MHC-peptide presentation remains stable among circulating SARS-CoV-2 viral strains.

Indexed as

COVID-19Epitopes, T-LymphocyteHLA AntigensSARS-CoV-2T-LymphocytesHaplotypesHumansLymphocyte ActivationEpitopes, T-LymphocyteHLA AntigensAPCHLA haplotypesNetMHCpanSARS‐CoV‐2T‐cell immunity

Identifiers

PMID40259456
PMCPMC12012228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.